

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON FOR TABLET CONTAINER

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Felidale 2.5 mg coated tablets for cats
Thiamazole

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

1 tablet contains:
Active substance:
Thiamazole 2.5 mg
Excipients:
Titanium dioxide (E171)
Erythrosine (E127)

3. PHARMACEUTICAL FORM

Coated tablets.

4. PACKAGE SIZE

100 coated tablets.

5. TARGET SPECIES

Cats.

6. INDICATIONS

For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy.
For the long-term treatment of feline hyperthyroidism.

7. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
For oral administration only.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNINGS, IF NECESSARY

Read the package leaflet before use.
For user warnings, please read the package leaflet.

10. EXPIRY DATE

EXP: {month/year}

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Keep the container tightly closed in order to protect from moisture.
Keep the container in the outer carton.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.
To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dechra Limited
Snaygill Industrial Estate
Keighley Road
Skipton
North Yorkshire
BD23 2RW
United Kingdom

16. MARKETING AUTHORISATION NUMBER

Vm 10434/4075

POM-V

17. MANUFACTURER’S BATCH NUMBER

Lot: {number}

OTHER INFORMATION

Veterinary medicinal product authorised for use in UK.

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON FOR BLISTER

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Felidale 2.5 mg
Coated tablets for cats
Thiamazole

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

1 tablet contains:
Active substance:
Thiamazole 2.5 mg
Excipients:
Titanium dioxide (E171)
Erythrosine (E127)

3. PHARMACEUTICAL FORM

Coated tablets.

4. PACKAGE SIZE

100 coated tablets.

5. TARGET SPECIES

Cats.

6. INDICATIONS

For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy.
For the long-term treatment of feline hyperthyroidism.

7. METHOD AND ROUTE OF ADMINISTRATION

Read the package leaflet before use.
For oral administration only.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNINGS, IF NECESSARY

Read the package leaflet before use.

For user warnings, please read the package leaflet.

10. EXPIRY DATE

EXP: {month/year}

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.

Keep the blister strips in the carton.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.

To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dechra Limited
Snaygill Industrial Estate
Keighley Road
Skipton
North Yorkshire
BD23 2RW
United Kingdom

16. MARKETING AUTHORISATION NUMBERS

Vm 10434/4075

POM-V

17. MANUFACTURER'S BATCH NUMBER

Lot: {number}

OTHER INFORMATION

Veterinary medicinal product authorised for use in UK.

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Felidale 2.5 mg coated tablets for cats
Thiamazole

2. QUANTITY OF THE ACTIVE SUBSTANCE

1 tablet contains:
Active substance:
Thiamazole 2.5 mg
Excipients:
Titanium dioxide (E171); Erythrosine (E127).

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

100 coated tablets.

4. ROUTE OF ADMINISTRATION

For oral administration only.
Read the package leaflet before use.

5. WITHDRAWAL PERIOD

Not applicable.

6. BATCH NUMBER

Lot: {number}

7. EXPIRY DATE

EXP: {month/year}

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

OTHER INFORMATION

Read the package leaflet before use for full instructions, including user warnings.

To be supplied only on veterinary prescription.

Veterinary medicinal product authorised for use in UK.

Marketing authorisation holder: Dechra Limited – UK

Vm 10434/4075

POM-V

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Felidale 2.5 mg
Coated tablets for cats
Thiamazole

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Dechra Limited

3. EXPIRY DATE

EXP:

4. BATCH NUMBER

Lot:

5. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET
Felidale 2.5 mg coated tablets for cats

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
AND OF THE MANUFACTURING AUTHORISATION HOLDER
RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Dechra Limited
Snaygill Industrial Estate
Keighley Road
Skipton
North Yorkshire
BD23 2RW
United Kingdom

Manufacturer responsible for batch release:

Genera Inc.,
Svetonedeljska cesta 2,
Kalinovica,
10436 Rakov Potok,
Croatia

Dales Pharmaceuticals Limited
Snaygill Industrial Estate
Keighley Road
Skipton
North Yorkshire
BD23 2RW
United Kingdom

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Felidale 2.5 mg coated tablets for cats
Thiamazole

3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS

1 tablet contains:

Active substance: Thiamazole 2.5 mg

Excipients: Titanium dioxide (E171); Erythrosine (E127).

Pink sugar-coated biconvex tablets.

4. INDICATIONS

For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy.
For the long-term treatment of feline hyperthyroidism.

5. CONTRAINDICATIONS

Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus.

Do not use in cats showing signs of autoimmune disease.

Do not use in animals with disorders of white blood cells, such as neutropaenia and lymphopaenia.

Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopaenia).

Do not use in cats with hypersensitivity to thiamazole or the excipient, polyethylene glycol.

Do not use in pregnant or lactating females.

Please refer to 'Special warnings'.

6. ADVERSE REACTIONS

Adverse reactions have been reported following long term control of hyperthyroidism. In many cases, signs may be mild and transitory and not a reason for withdrawal of treatment. The more serious effects are mainly reversible when medication is stopped.

Adverse reactions are uncommon. The most common clinical side effects that are reported include vomiting, inappetance/anorexia, lethargy, severe pruritus and excoriations of the head and neck, bleeding diathesis and icterus associated with hepatopathy, and haematological abnormalities (eosinophilia, lymphocytosis, neutropaenia, lymphopaenia, slight leucopenia, agranulocytosis, thrombocytopaenia or haemolytic anaemia). These side effects resolve within 7-45 days after cessation of thiamazole therapy.

Possible immunological side effects include anaemia, with rare side effects including thrombocytopaenia and serum anti-nuclear antibodies, and, very rarely, lymphadenopathy. Treatment should be stopped immediately and alternative therapy considered following a suitable period for recovery.

Following long-term treatment with thiamazole in rodents, an increased risk of neoplasia in the thyroid gland has been shown to occur, but no evidence is available in cats.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Cats.

8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For oral administration only.

For the stabilisation of feline hyperthyroidism prior to surgical removal of the thyroid gland, one 2.5 mg tablet morning and evening. This should ensure euthyroidism within 3 weeks in most cases.

For long-term treatment of hyperthyroidism, the starting dose should be 2.5 mg twice daily. After 3 weeks, the dose should be titrated to effect according to the serum total T₄. Dose adjustments should be made by increments of 2.5 mg. Wherever possible, the total daily dose should be divided into two and administered morning and

evening. Tablets should not be split. The aim should be to achieve the lowest possible dose rate.

If, for reasons of compliance, once a day dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime. The 5 mg tablet is also suitable for cats requiring higher dose rates. The dose administered must not exceed 20 mg/day.

For long-term treatment of hyperthyroidism the animal should be treated for life.

9. ADVICE ON CORRECT ADMINISTRATION

Haematology, biochemistry and serum total T₄ should be assessed before initiating treatment and after 3 weeks, 6 weeks, 10 weeks, 20 weeks and thereafter every 3 months and the dose titrated as necessary. If more than 10 mg per day is required animals should be monitored particularly carefully.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Do not store above 25°C.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.

Tablet container: Keep the container tightly closed in order to protect from moisture. Keep the container in the outer carton.

Blister: Keep the blister strips in the carton.

12. SPECIAL WARNINGS

Special precautions for use in animals:

As thiamazole can cause haemoconcentration, cats should always have access to drinking water.

If more than 10 mg per day is required animals should be monitored particularly carefully.

Use of the product in cats with renal dysfunction should be subject to careful risk - benefit assessment by the clinician. Due to the effect thiamazole can have on reducing the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying condition may occur.

Haematology must be monitored due to risk of leucopenia or haemolytic anaemia.

Any animal that suddenly appears unwell during therapy, particularly if they are febrile, should have a blood sample taken for routine haematology and biochemistry.

Neutropenic animals (neutrophil counts <2.5 x 10⁹/l) should be treated with prophylactic bactericidal antibacterial drugs and supportive therapy (please refer to section "Amounts to be administered and administration route" for monitoring instructions).

Use during pregnancy, lactation or lay:

Laboratory studies in rats and mice have shown evidence of teratogenic and embryotoxic effects of thiamazole. The safety of the product was not assessed in pregnant or lactating cats. Do not use in pregnant or lactating females.

Interaction with other medicinal products and other forms of interaction:

If your cat is being treated with any other medications advise your veterinary surgeon prior to the use of Felidale.

Concurrent treatment with phenobarbital may reduce the clinical efficacy of thiamazole.

Thiamazole is known to reduce the hepatic oxidation of benzimidazole wormers and may lead to increases in their plasma concentrations when given concurrently.

Thiamazole is immunomodulatory, therefore this should be taken into account when considering vaccination programmes.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after use.

In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Thiamazole may cause vomiting, epigastric distress, headache, fever, arthralgia, pruritus and pancytopenia. Treatment is symptomatic.

Wash hands with soap and water after handling litter used by treated animals.

Do not eat, drink or smoke while handling the tablet or used litter.

Do not handle this product if you are allergic to antithyroid products. If allergic symptoms develop, such as a skin rash, swelling of the face, lips or eyes or difficulty in breathing, you should seek medical attention immediately and show the package leaflet or label to the doctor.

Do not break or crush tablets.

As thiamazole is a suspected human teratogen, women of child-bearing age should wear gloves when handling litter of treated cats.

Pregnant women should wear gloves when handling the product.

Overdose (symptoms, emergency procedures, antidotes):

In tolerance studies in young healthy cats, the following dose-related clinical signs occurred at doses of up to 30 mg/animal/day: anorexia, vomiting, lethargy, pruritus and haematological and biochemical abnormalities such as neutropaenia, lymphopaenia, reduced serum potassium and phosphorus levels, increased magnesium and creatinine levels and the occurrence of anti-nuclear antibodies. At a dose of 30 mg/day some cats showed signs of haemolytic anaemia and severe clinical deterioration. Some of these signs may also occur in hyperthyroid cats treated at doses of up to 20 mg per day.

Excessive doses in hyperthyroid cats may result in signs of hypothyroidism. This is however unlikely, as hypothyroidism is usually corrected by negative feedback mechanisms. Please refer to the section 'Adverse reactions'.

If overdosage occurs, stop treatment and immediately contact your veterinary surgeon.

Give symptomatic and supportive care.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

03/2019

15. OTHER INFORMATION

For animal treatment only.
To be supplied only on veterinary prescription.
Container of 100 tablets.
Blister pack of 100 tablets.
Not all pack sizes may be marketed.
Veterinary medicinal product authorised for use in UK.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.
Dechra Veterinary Products Limited, Sansaw Business Park, Hadnall, Shrewsbury, Shropshire, SY4 4AS, UK.

Vm 10434/4075	POM-V
---------------	-------

Approved: 18 June 2019

